NICE approves mpMRI as a first-line investigation for localised prostate cancer

  • National Institute for Health and Care Excellence

  • curated by Dawn O'Shea
  • Medical news
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

NICE has approved multiparametric MRI (mpMRI) as a first-line investigation for localised prostate cancer.

In draft guidance published today (12 December 2018), NICE has recommended first-line mpMRI for men with suspected clinically localised prostate cancer. It advises that mpMRI findings should be reported using a five-point Likert scale.

The guidance also recommends that mpMRI-influenced prostate biopsy should be offered to patients with a Likert score of three or more.

Research has shown mpMRI to be clinically cost-effective. The modality has been associated with a reduced number of biopsies as well as the cost savings involved in earlier diagnosis.  

NICE says physicians should, “consider omitting a prostate biopsy for people whose multiparametric MRI Likert score is 1 or 2, but only after discussing the risks and benefits with the person and reaching a shared decision.” Systematic prostate biopsy should be offered to men who opt for biopsy.

Commenting on the guidance, Paul Chrisp, Director for the NICE Centre for Guidelines said: “We are pleased to announce that we will be recommending multiparametric MRI for patients with prostate cancer."

“This diagnostic pathway will hopefully improve survival, reduce unnecessary surgery and benefit both patients and the NHS in the long term,” he said.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit